BiotechTube

AZD9977 oral suspension + AZD9977 placebo oral suspension + Fludrocortisone, tablets + Eplerenone, tablets

Phase 1Completed
0 watching 0 views this week💤 Quiet
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Pharmacodynamics

Conditions

Pharmacodynamics, Healthy Subjects

Trial Timeline

Sep 1, 2015 → Dec 1, 2015

NCT ID
NCT02532998

About AZD9977 oral suspension + AZD9977 placebo oral suspension + Fludrocortisone, tablets + Eplerenone, tablets

AZD9977 oral suspension + AZD9977 placebo oral suspension + Fludrocortisone, tablets + Eplerenone, tablets is a phase 1 stage product being developed by AstraZeneca for Pharmacodynamics. The current trial status is completed. This product is registered under clinical trial identifier NCT02532998. Target conditions include Pharmacodynamics, Healthy Subjects.

Hype Score Breakdown

Clinical
10
Activity
5
Company
10
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT02532998Phase 1Completed

Competing Products

6 competing products in Pharmacodynamics

See all competitors
ProductCompanyStageHype Score
GP40141 + NplateGEROPHARMPhase 1
25
AZD7986, oral solution, 1 to 50 mg/mL + Placebo, oral solutionAstraZenecaPhase 1
33
D961H + OmeprazoleAstraZenecaPhase 1
33
Dienogest (81150037) + Dienogest (81150231) + Dienogest (SH T00660A) + Dienogest (81150746)BayerPhase 1
30
5 mg ACT-281959 prodrug formulation I (Group A) + 20 mg ACT-281959 prodrug formulation I (Group B) + ACT-281959 prodrug formulation I (Groups C to G doses to be defined) + ACT-281959 prodrug formulation II (Group G dose to be defined) + ACT-246475 (Group G dose to be defined) + Placebo (Groups A to F)IdorsiaPhase 1
28
VXA-A1.1 H1 Tablet Vaccine (small) + VXA-A1.1 H1 Tablet Vaccine (large)VaxartPhase 1
25

Other Products from AstraZeneca

QuetiapineApproved
85
Dapagliflozin 5 mg + Placebo tabletApproved
85
QuetiapineApproved
85
Ticagrelor + ClopidogrelApproved
85
DurvalumabApproved
85